Phase 1 Trial Assessing PET Imaging Agent in Local and Advanced Prostate Cancers Enrolling Patients

Phase 1 Trial Assessing PET Imaging Agent in Local and Advanced Prostate Cancers Enrolling Patients
Cancer Targeted Technology (CTT) has initiated a Phase 1 clinical trial evaluating the safety and sensitivity of its positron emission tomography (PET) imaging agent, CTT1057, in detecting prostate cancer cells in patients with both localized and metastatic disease. The trial is supported by a $2 million Small Business Innovation Research (SBIR) grant, and imaged its first patients in early November. CTT1057, which was designated an Investigational New Drug by the U.S. Food and Drug Administration in August, is a radiolabeled (fluorine-18) antibody that binds to the prostate cancer biomarker PSMA irreversibly, enhancing the imaging agent's uptake by cancer cells. Because PSMA is expressed
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *